Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
Get Alerts AVDL Hot Sheet
Join SI Premium – FREE
DUBLIN, May 30, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:
- Jefferies Global Healthcare Conference: Fireside chat on Thursday, June 6 at 10:30 a.m. ET.
- Goldman Sachs 45th Annual Global Healthcare Conference: Fireside chat on Wednesday, June 12 at 3:20 p.m. ET.
A live webcast of these events, as well as archived recordings, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following each conference.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:Courtney MogerleyPrecision AQ[email protected](212) 698-8687
Media Contact:Lesley StanleyReal Chemistry[email protected] (609) 273-3162
Source: Avadel Pharmaceuticals plc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Membrane Solutions Launches New Outdoor Water Filtration Solutions at Outdoor Retailer 2026
- Best AI Meme Coin Presale 2026: MemeToro Combines AI Agents With BNB Chain Infrastructure
- Green Electricity Illuminates Indoor Ski Resort in Central China
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Goldman Sachs, Jefferies & Co, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share